PLACEHOLDER: Free shipping over $XX — confirm threshold

Topical cosmetics and devices only — not for injection

Cellular Sequence

Peptide Encyclopaedia

Approved medicineApproved medicine

Teduglutide

Also known as Gattex, Revestive.

Approved-medicine listing only. This is not available from the Cellular Sequence shop. Licensed products require a prescriber and an ARTG-registered presentation.

At-a-glance profile

Classification
GLP-2 analogue
Approval status
Approved medicine
Research status
Labelled indications are defined in product information.
Molecular formula
Insufficient reliable evidence identified.
Molecular weight
Insufficient reliable evidence identified.
Sequence
Recombinant GLP-2 analogue with substitution for DPP-4 resistance.
Primary biological target
Glucagon-like peptide-2 receptor
Half-life
Insufficient reliable evidence identified.
Routes investigated
Subcutaneous
Human evidence level
A — Approved clinical use / strong human evidence

What is it?

Approved for short-bowel syndrome in eligible patients dependent on parenteral support, as labelled.

Mechanism of action

Established (labelled / textbook receptor pharmacology)

GLP-2 receptor agonism promotes intestinal mucosal growth and absorption in labelled SBS care.

May reduce parenteral nutrition volume in labelled SBS — specialist use.

What is it being studied for?

  • Short bowel syndrome

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: A · Approved clinical use / strong human evidence

Human research

Pivotal SBS trials support labelling.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

GLP-2 intestinotrophic biology is established.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

GI symptoms; neoplastic risk discussions in PI (colon surveillance).

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. See PI (active GI malignancy considerations).

Regulatory status

FDA/EMA approved for SBS.

Verify ARTG. Not sold here.

Citations

  1. [1] Teduglutide for short bowel syndrome

    Teduglutide for short bowel syndrome

    Open source

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Metabolic · Compare peptides